Gilead Sciences Inc. (GILD)
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
Gilead Sciences, Inc. ( GILD ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury and Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President of Kite Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research Christopher Schott - JPMorgan Chase & Co, Research Division James Shin - Deutsche Bank AG, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van Buren - TD Cowen, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
What To Expect From Gilead In Q3 2025
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead's Trodelvy cuts breast cancer risk by 38% in trial
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism, with FDA approval and delayed Biktarvy exclusivity boosting long-term prospects. Valuation remains attractive, with technical analysis signaling potential upside to $150 in the near term and $185 longer term.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an additional 100% tariff on Chinese goods starting November 1st.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
